Sargent Investment Group LLC Has $7.67 Million Position in Exelixis, Inc. (NASDAQ:EXEL)

Sargent Investment Group LLC cut its stake in Exelixis, Inc. (NASDAQ:EXEL) by 6.5% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 217,212 shares of the biotechnology company’s stock after selling 15,033 shares during the quarter. Exelixis makes up about 1.2% of Sargent Investment Group LLC’s holdings, making the stock its 20th biggest holding. Sargent Investment Group LLC’s holdings in Exelixis were worth $7,668,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in EXEL. Seizert Capital Partners LLC grew its position in Exelixis by 8.0% in the third quarter. Seizert Capital Partners LLC now owns 469,940 shares of the biotechnology company’s stock valued at $12,195,000 after purchasing an additional 34,875 shares in the last quarter. Los Angeles Capital Management LLC lifted its holdings in Exelixis by 124.0% during the 3rd quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company’s stock worth $46,473,000 after purchasing an additional 991,494 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Exelixis by 60.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 54,863 shares of the biotechnology company’s stock worth $1,424,000 after buying an additional 20,641 shares in the last quarter. Tri Ri Asset Management Corp acquired a new position in shares of Exelixis during the 3rd quarter worth approximately $4,396,000. Finally, CWA Asset Management Group LLC bought a new position in Exelixis during the 3rd quarter worth $577,000. Institutional investors and hedge funds own 85.27% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently weighed in on EXEL. Guggenheim restated a “buy” rating on shares of Exelixis in a research report on Wednesday, January 22nd. Brookline Capital Management assumed coverage on Exelixis in a research report on Monday, December 23rd. They set a “buy” rating for the company. Morgan Stanley raised shares of Exelixis from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $30.00 to $40.00 in a research note on Monday, January 27th. UBS Group lifted their target price on Exelixis from $30.00 to $34.00 and gave the stock a “neutral” rating in a report on Tuesday, January 28th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $41.00 target price on shares of Exelixis in a research report on Thursday, January 23rd. One analyst has rated the stock with a sell rating, seven have issued a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $36.06.

Insider Activity

In other news, EVP Patrick J. Haley sold 10,000 shares of the company’s stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $35.27, for a total transaction of $352,700.00. Following the transaction, the executive vice president now directly owns 278,665 shares of the company’s stock, valued at approximately $9,828,514.55. This represents a 3.46 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Jeffrey Hessekiel sold 60,000 shares of the firm’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $36.67, for a total value of $2,200,200.00. Following the completion of the transaction, the executive vice president now owns 486,059 shares of the company’s stock, valued at approximately $17,823,783.53. The trade was a 10.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 111,588 shares of company stock valued at $3,981,864. Corporate insiders own 2.85% of the company’s stock.

Exelixis Trading Up 0.7 %

Shares of NASDAQ EXEL opened at $33.12 on Wednesday. The stock has a market capitalization of $9.46 billion, a price-to-earnings ratio of 21.23, a P/E/G ratio of 0.72 and a beta of 0.53. Exelixis, Inc. has a 12-month low of $20.01 and a 12-month high of $37.59. The firm’s 50-day moving average price is $34.54 and its 200-day moving average price is $30.33.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.